Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2004-07-30
2009-11-03
Woodward, M P (Department: 1615)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C424S473000, C424S484000
Reexamination Certificate
active
07612112
ABSTRACT:
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3977404 (1976-08-01), Theeuwes
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4152326 (1979-05-01), Hartenstein et al.
patent: 4309406 (1982-01-01), Guley et al.
patent: 4462839 (1984-07-01), McGinley et al.
patent: 4612008 (1986-09-01), Wong et al.
patent: 4894476 (1990-01-01), Butler et al.
patent: 4996058 (1991-02-01), Sinnreich
patent: 5007790 (1991-04-01), Shell
patent: 5084479 (1992-01-01), Woodruff
patent: 5232704 (1993-08-01), Franz et al.
patent: 5582837 (1996-12-01), Shell
patent: 5872984 (1999-02-01), Berglund et al.
patent: 5906832 (1999-05-01), Jao et al.
patent: 5972389 (1999-10-01), Shell et al.
patent: 6024982 (2000-02-01), Oshlack et al.
patent: 6054482 (2000-04-01), Augart et al.
patent: 6120803 (2000-09-01), Wong et al.
patent: 6162466 (2000-12-01), Licht et al.
patent: 6255526 (2001-07-01), Pesachovich et al.
patent: 6273340 (2001-08-01), Rivailler
patent: 6294690 (2001-09-01), Deering et al.
patent: 6310098 (2001-10-01), Guttuso, Jr.
patent: 6333352 (2001-12-01), Derakhshan
patent: 6340475 (2002-01-01), Shell et al.
patent: 6350471 (2002-02-01), Seth
patent: 6451808 (2002-09-01), Cowles
patent: 6488962 (2002-12-01), Berner et al.
patent: 6488964 (2002-12-01), Bruna et al.
patent: 6635280 (2003-10-01), Shell et al.
patent: 6635281 (2003-10-01), Wong et al.
patent: 6682759 (2004-01-01), Lim et al.
patent: 6683112 (2004-01-01), Chen et al.
patent: 6723340 (2004-04-01), Berner et al.
patent: 2001/0043946 (2001-11-01), Vilkov
patent: 2002/0012679 (2002-01-01), Bruna et al.
patent: 2002/0115705 (2002-08-01), Magnus-Miller et al.
patent: 2003/0031711 (2003-02-01), Fara et al.
patent: 2003/0044466 (2003-03-01), Markey et al.
patent: 2003/0091630 (2003-05-01), Berner et al.
patent: 2003/0100611 (2003-05-01), Berner et al.
patent: 2003/0104052 (2003-06-01), Berner et al.
patent: 2003/0104053 (2003-06-01), Gusler et al.
patent: 2003/0104062 (2003-06-01), Berner et al.
patent: 2003/0133985 (2003-07-01), Berner et al.
patent: 2003/0152622 (2003-08-01), Berner et al.
patent: 2004/0062802 (2004-04-01), Hermelin
patent: 2005/0064036 (2005-03-01), Berner et al.
patent: 2006/0094785 (2006-05-01), Guttuso Jr
patent: 2006/0159743 (2006-07-01), Berner et al.
patent: 2006/0264509 (2006-11-01), Fraser et al.
patent: 2220038 (1999-07-01), None
patent: 0 458 751 (1991-05-01), None
patent: 1 118 321 (2001-07-01), None
patent: WO-98/55107 (1998-12-01), None
patent: WO 01/13894 (2001-03-01), None
patent: WO 01/97612 (2001-12-01), None
patent: WO 01/97782 (2001-12-01), None
patent: WO-03/002101 (2003-01-01), None
patent: WO 03/002151 (2003-01-01), None
patent: WO-03/035040 (2003-01-01), None
Hou et al., “Gastric Retentive Dosage Forms: A Review,” Crit. Rev. Ther. Drug Carrier Syst. (2003) 20(6):461-497.
Bennett et al. (2004) “Gabapentin in the treatment of neurophathic pain”Palliative Med., 18(1):5-11.
Richter et al. (Nov. 2005) “Pregabalin or morphine and gabapentin for neuropathic pain”Expert Op. on Pharmacotherapy, 6(14):2535-2539.
Wesche et al. (Mar. 2005) “A pharmacokinetic comparison of pregabalin and gabapentin”J. of Pain, 6(3), abstract only.
NDA 20-235 (U.S. Food and Drug Administration application No. 020235).
Guttuso Jr. et al. (Feb. 2003) “Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial”Am. College of Obstetricians and Gynecologists, 101(2):337-345.
Laird et al. (Jun. 2000) “Use of gabapentin in the treatment of neuropathic pain”Ann. Pharmacotherapy, 34:802-807.
Goa et al. (1993) “Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy”Drugs46(3):409-427.
Wheeler, G. (2002) “Gabapentin”Curr. Op. Invest. Drugs, 3(3):470-477.
Benetello et al. (1997) “Oral gabapentin disposition in patients with epilepsy after a high-protein meal”Epilepsia, 38(10):1140-1142.
Piyapolrungroj et al. (2001) “Mucosal uptake of gabapentin (neurontin) vs. pregabalin in the small intestine”Pharm. Res. 18(8):1126-1130.
Bennett et al. (Aug. 2000) “Future directions in the management of pain by intraspinal drug delivery”J. Pain and Symptom Management, 20(2):S44-S50.
Stevenson et al. (Aug. 1997) “Contrasting nutrient effects on the plasma level of an amino acid-like antiepileptic agent from jejunal administration in dogs”J. Pharm. Sci. 86(8):953-957.
Solaro et al. (2000) “Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis”Multiple Sclerosis, 6:192-193.
U.S. Appl. No. 09/425,491, Shell et al.
U.S. Appl. No. 10/045,816, Berner et al.
Andrews et al. (1994) “Gabapentin: a New Agent for the Management of Epilepsy,”Annals of Pharmacotherapy28: 1188-1196.
Asconape et al. (2000) “Myoclonus Associated with the Use of Gabapentin,”Epilepsia: 41(4): 479-481.
Backonja et al. (1998) “Gabapentin for the Symptomatic Treatment of Painful Neuropathy in Patients with Diabetes Mellitus,”JAMA280(21): 1831-1836.
Bebin et al. (1994) “New Anticonvulsant Drugs: Focus on Flunarizine, Fosphenytoin, Midazolam, and Stiripentol,”Drugs48(2): 153-171.
Benedetti (2000) “Enzyme Induction and Inhibition by New Antiepileptic Drugs: a Review of Human Studies,”Fundam. Clin. Pharmacol. 14: 301-319.
Ben-Menachem (2000) “New Antiepileptic Drugs and Non-pharmacological Treatments,”Current Opinion in Neurology13: 165-170.
Bennett et al. (2000) “Future Directions in the Management of Pain by Intraspinal Drug Delivery,”Journal of Pain and Symptom Management20(2): 244-250.
Bernus et al. (1997) “Anticonvulsant Therapy in Aged Patients: Clinical Pharmacokinetic Considerations,”Drugs & Aging10(4): 278-289.
Beydoun (1997) “Monotherapy Trial of New Antiepileptic Drugs,”Epilepsia38(Supp. 9): S21-S31.
Bialer (1993) “Comparative Pharmacokinetics of the Newer Antiepileptic Drugs,”Clinical Pharmacokinetics24(6): 441-452.
Blum et al. (1994) “Pharmacokinetics of Gabapentin in Subject with Various Degrees of Renal Function,”Clinical Pharmacology and Therapeutics56(2): 154-159.
Bourgeois (1998) “New Antiepileptic Drugs,”Arch Neuro. 55: 1181-1183.
Bourgeois (1995) “Important Pharmacokinetic Properties of Antiepileptic Drugs,”Epilepsia36 (Supp. 5): S1-S7.
Bourgeouis (2000) “Pharmacokinetic Properties of Current Antiepileptic Drugs: What improvements are Needed?”Neurology55(Supp. 3): S11-S16.
Boyd et al. (1999) “Clinical Research: Effects of Age and Gender on Single-Dose Pharmacokinetics of Gabapentin,”Epilepsia40(4): 474-479.
Brown et al. (1998) “Cloning and Deletion Mutagenesis of the α2δ Calcium Channel Subunit from Porcine Cerebral Cortex,”Journal of Biological Chemistry273(39): 25458-25465.
Browne (1993) “Long-Term Efficacy and Toxicity of Gabapentin,”Neurology43: A307.
Chadwick (1994) “Gabapentin,”Lancet343: 89-91.
Chadwick (1997) “An Overview of the Efficacy and Tolerability of New Antiepileptic Drugs,”Epilepsia38(Supp. 1): S59-S62.
Chadwick et al. (1996) “Clinical Administration of New Antiepileptic Drugs: An Overview of Safety and Efficacy,”Epilepsia37 (Supp. 6): S17-S22.
Cramer et al. (1999) “New Antiepileptic Drugs: Comparison of Key Clinical Trials,”Epilepsia40(5): 590-600.
Curry et al. (1998) “Newer Antiepileptic Drugs: Gabapentin, Lamotrigine, Felbamate, Topirimate, and Fosphenytoin,”American Family Physician57(3): 513-520.
Devinsky et al. (1994) “New Antiepileptic Drugs for Children: Felbamate, Gabapentin, Lamotrigine, and Vigabatrin,”Journal of Child Neurology9 (S
Berner Bret
Gusler Gloria M.
Hou Sui Yuen Eddie
Depomed Inc.
Harlocker Susan L.
Mohr Judy M.
Sasan Aradhana
Simboli Paul B.
LandOfFree
Methods of treatment using a gastric retained gabapentin dosage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treatment using a gastric retained gabapentin dosage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treatment using a gastric retained gabapentin dosage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4103295